Young Kwang Chae, MD, MPH, MBA· @youngkwangchae · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Targeting the "undruggable" KRAS G12D just got a major boost at #AACR26!
Zoldonrasib (RMC-9805) data in pre-treated NSCLC presented by
@riess_md
Efficacy: 52% ORR | 93% DCR
Durability: mPFS 11.1 months (12-mo PFS: 48%) | mDOR: NE (95% CI: 8.3–NE)
Safety: Favorable
Heat 24 · 15 likes · 0 replies · 9 reposts
Source: Young Kwang Chae, MD, MPH, MBA · x.com